Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) have been given an average recommendation of “Moderate Buy” by the four analysts that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating and three have issued a buy rating on the company. The average 1 year target price among analysts that have covered the stock in the last year is $15.00.

A number of research firms have commented on VYGR. Wall Street Zen downgraded Voyager Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, February 21st. HC Wainwright lowered their price target on Voyager Therapeutics from $30.00 to $25.00 and set a “buy” rating for the company in a report on Wednesday, November 12th.

Insider Buying and Selling

In other Voyager Therapeutics news, CEO Alfred Sandrock sold 14,197 shares of the stock in a transaction dated Tuesday, February 24th. The shares were sold at an average price of $3.79, for a total transaction of $53,806.63. Following the completion of the transaction, the chief executive officer owned 484,060 shares of the company’s stock, valued at $1,834,587.40. This trade represents a 2.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders have sold a total of 49,783 shares of company stock valued at $188,694 over the last 90 days. Corporate insiders own 6.39% of the company’s stock.

Hedge Funds Weigh In On Voyager Therapeutics

Several large investors have recently made changes to their positions in VYGR. EcoR1 Capital LLC boosted its position in shares of Voyager Therapeutics by 497.2% during the 4th quarter. EcoR1 Capital LLC now owns 4,002,847 shares of the company’s stock worth $15,731,000 after purchasing an additional 3,332,544 shares during the period. Vanguard Group Inc. raised its position in Voyager Therapeutics by 1.3% in the third quarter. Vanguard Group Inc. now owns 3,250,066 shares of the company’s stock valued at $15,178,000 after purchasing an additional 40,147 shares during the period. Opaleye Management Inc. acquired a new position in Voyager Therapeutics during the fourth quarter worth $4,704,000. Erste Asset Management GmbH lifted its stake in Voyager Therapeutics by 7.0% during the fourth quarter. Erste Asset Management GmbH now owns 1,195,141 shares of the company’s stock worth $4,718,000 after purchasing an additional 78,348 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Voyager Therapeutics by 1.1% during the second quarter. Geode Capital Management LLC now owns 1,116,847 shares of the company’s stock worth $3,474,000 after buying an additional 11,929 shares during the period. 48.03% of the stock is currently owned by institutional investors and hedge funds.

Voyager Therapeutics Price Performance

Voyager Therapeutics stock opened at $4.85 on Thursday. The firm has a 50 day simple moving average of $3.89 and a 200-day simple moving average of $4.16. The stock has a market cap of $269.66 million, a price-to-earnings ratio of -2.39 and a beta of 1.32. Voyager Therapeutics has a 1-year low of $2.64 and a 1-year high of $5.55.

Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings results on Monday, March 9th. The company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.08. Voyager Therapeutics had a negative net margin of 296.53% and a negative return on equity of 51.35%. The firm had revenue of $13.46 million for the quarter, compared to analyst estimates of $10.49 million. Equities analysts expect that Voyager Therapeutics will post -0.91 earnings per share for the current fiscal year.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.